登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、通知债权人的原因 科大智能科技股份有限公司（以下简称"公司"）于2025年10月27日和2025年11月14日分别召开第六届董 事会第七次会议和2025年第四次临时股东会审议通过了《关于使用公积金弥补亏损的议案》。 根据容诚会计师事务所（特殊普通合伙）出具的审计报告（容诚审字[2025]230Z0149号），截至2024年 12月31日，公司母公司报表未分配利润为-2,592,965,182.72元，盈余公积33,244,430.45元，资本公积 3,549,082,452.81元。 根据《中华人民共和国公司法》等法律、法规及规范性文件，以及《公司章程》的相关规定，公司拟使 用母公司盈余公积33,244,430.45元和资本公积2,559,720,752.27元，两项合计2,592,965,182.72元用于弥补 母公司累计亏损。具体内容详见公司于2025年10月28日披露的《关于使用公积金弥补亏损的公告》（公 告编号：2025-073）。 根据《中华人民共和 ...

Core Viewpoint - The announcement by CanSino Biologics regarding the use of capital reserves to cover losses has sparked significant investor discussion, highlighting concerns over the treatment of minority shareholders and the company's financial management practices [1][2]. Financial Summary - CanSino plans to use approximately 1.18 billion yuan from surplus reserves and 13.32 billion yuan from capital reserves, totaling about 14.5 billion yuan, to offset cumulative losses, bringing its negative retained earnings to zero [1][3]. - As of December 31, 2024, CanSino's financial statements indicated a negative retained earnings of approximately -14.5 billion yuan, with surplus reserves of about 1.18 billion yuan and capital reserves of approximately 65.77 billion yuan [3]. - Following the implementation of this plan, the surplus reserves will be reduced to zero, capital reserves will decrease to about 52.45 billion yuan, and retained earnings will be adjusted to zero [3]. Historical Performance - CanSino has only issued one cash dividend since its IPO, amounting to approximately 198 million yuan, with a dividend yield of 0.27% [4]. - The company achieved profitability only in 2021, with a net profit of 1.914 billion yuan, but has faced losses in subsequent years due to declining demand for COVID-19 vaccines [4][5]. - In 2022, CanSino's revenue dropped by 75.94%, resulting in a net loss of approximately 909 million yuan, primarily due to a significant decrease in COVID-19 vaccine sales [5]. Recent Developments - In the third quarter of 2023, CanSino reported a net profit of approximately 27.93 million yuan, marking a significant turnaround from previous losses [1][6]. - The company's revenue for the first three quarters of 2023 was approximately 693 million yuan, a year-on-year increase of 22.13% [6]. - The growth in revenue was driven by the sales of its quadrivalent meningococcal vaccine, which achieved a market share increase and generated sales of approximately 662 million yuan, up 28% year-on-year [6]. Cost Management and Funding - CanSino's R&D expenses decreased by about 18% to 225 million yuan, attributed to the advancement of several projects to phase III clinical trials [7]. - The company received approximately 24.09 million yuan in government subsidies and 60.02 million yuan in international funding support during the first three quarters of 2023 [7]. - Despite the positive revenue growth, CanSino's net profit excluding non-recurring items was approximately -82.86 million yuan, indicating ongoing financial challenges [8].

Core Points - The company, Xinjiang Baihua Village Pharmaceutical Group Co., Ltd., held its second extraordinary general meeting of shareholders on November 12, 2025, where it approved the use of surplus reserves to cover losses totaling 1,910,537,976.55 yuan [2][3][4] Trading Information - As of November 13, 2025, the stock price of Baihua Pharmaceutical closed at 9.59 yuan, an increase of 4.92%, with a turnover rate of 8.81% and a trading volume of 338,800 shares, amounting to a total transaction value of 322 million yuan [1] - On the same day, the net inflow of main funds was 38.9982 million yuan, accounting for 12.1% of the total transaction value, while retail investors experienced a net outflow of 18.9483 million yuan, representing 5.88% of the total transaction value [1][4] Shareholder Meeting Details - The extraordinary general meeting was attended by 288 shareholders and representatives, representing 30.7320% of the total voting shares [2] - The resolution to use surplus reserves to cover losses received 99.4827% approval from the voting shareholders present, with only 0.4686% opposing and 0.0487% abstaining [1][2]

Core Viewpoint - The company held its third extraordinary general meeting of shareholders on November 12, 2025, where it approved the use of reserve funds to cover losses and signed a financial services agreement with China Merchants International Financial Co., Ltd [2][4][9]. Group 1: Meeting Details - The extraordinary general meeting was held on November 12, 2025, at the company's headquarters in Nanjing [2]. - The meeting was conducted in accordance with the Company Law and the company's articles of association, combining in-person attendance and online voting [2][3]. - Six out of nine directors attended the meeting, with the chairman and two other directors absent due to work commitments [3]. Group 2: Resolutions Passed - The first resolution approved the use of reserve funds to cover losses, which was passed by a majority of the voting rights held by attending shareholders [4][5]. - The second resolution involved signing a financial services agreement with China Merchants International Financial Co., Ltd, which was also approved [4][5]. Group 3: Financial Information - As of December 31, 2024, the company reported an accumulated loss of approximately 1.57 billion yuan, with a surplus reserve of about 3.19 million yuan and a capital reserve of approximately 4.28 billion yuan [9]. - The company plans to use 3.19 million yuan from the surplus reserve and approximately 1.57 billion yuan from the capital reserve to cover the accumulated losses [9]. Group 4: Legal Compliance - The meeting was witnessed by lawyers from Shanghai Hai Fu Law Firm, confirming that the meeting's procedures complied with legal and regulatory requirements [6].

Core Viewpoint - The company, China Merchants Jinling Shipping Company, held its third extraordinary general meeting on November 12, 2025, where it approved two key resolutions regarding the use of reserve funds to cover losses and a financial service agreement with China Merchants International Financial Co., Ltd [2][4]. Trading Information Summary - As of November 12, 2025, the stock price of China Merchants Jinling Shipping Company closed at 3.3 yuan, with an increase of 0.92%. The turnover rate was 2.67%, with a trading volume of 1.28 million shares and a total transaction value of 420 million yuan [1]. - On the same day, the net inflow of main funds was 17.88 million yuan, accounting for 4.26% of the total transaction value. In contrast, retail investors experienced a net outflow of 9.26 million yuan, representing 2.21% of the total transaction value [1][4]. Company Announcement Summary - The third extraordinary general meeting of China Merchants Jinling Shipping Company was legally convened, with 1,045 shareholders and proxies present, representing 36.7547% of the voting rights [2]. - The meeting approved the proposal to use reserve funds to cover losses, utilizing 3,193,890.66 yuan from surplus reserves and 1,570,911,748.21 yuan from capital reserves to offset cumulative losses as of December 31, 2024 [3]. - The second proposal regarding the signing of a financial service agreement with China Merchants International Financial Co., Ltd. was also approved, although the related shareholder, China Yangtze Shipping Group Co., Ltd., did not participate in the voting [2].

Core Points - Baihua Pharmaceutical (600721) closed at 8.96 yuan on November 7, 2025, down 0.33% from 8.99 yuan the previous week [1] - The company's total market capitalization is 3.446 billion yuan, ranking 45th out of 50 in the medical services sector and 4303rd out of 5166 in the A-share market [1] Company Announcements - Baihua Pharmaceutical plans to use surplus reserves of 5,030,274.41 yuan and capital reserves of 1,905,507,702.14 yuan to offset accumulated losses [1] - As of December 31, 2024, the parent company's accumulated undistributed profits stand at -1,910,537,976.55 yuan, with surplus reserves of 5,030,274.41 yuan and capital reserves of 2,260,280,858.86 yuan [1] - The total amount to be used for loss offsetting is 1,910,537,976.55 yuan, which will bring undistributed profits to zero [1] - The plan aims to improve the financial situation, enable profit distribution, and enhance investor return capabilities [1] - This proposal has been submitted for review at the second extraordinary general meeting of shareholders in 2025 [1]

Group 1 - The company will hold its second extraordinary general meeting of shareholders on November 27, 2025 [2] - A temporary proposal has been added to the agenda, suggesting the use of capital reserves to cover losses [3][19] - The proposal was submitted by Dr. Xuefeng Yu, who holds 7.26% of the company's shares [2][3] Group 2 - The meeting will take place at the Tianjin East Hyatt Hotel, starting at 14:00 [5] - Shareholders can vote online through the Shanghai Stock Exchange's voting system on the day of the meeting [7] - The original date for the equity registration remains unchanged [8] Group 3 - The company reported a cumulative undistributed profit of -1,450,342,128.90 yuan as of December 31, 2024 [17] - The plan involves using 118,388,703.29 yuan from surplus reserves and 1,331,953,425.61 yuan from capital reserves to offset losses [18] - After the implementation of this plan, the company's surplus reserves will be reduced to 0 yuan, and capital reserves will decrease to 5,244,776,299.42 yuan [19] Group 4 - The proposal to use capital reserves to cover losses has been approved by the company's board and supervisory board [20] - The company aims to enhance investor returns and promote high-quality development through this measure [19] - The proposal requires approval from the shareholders' meeting, indicating a level of uncertainty [21] Group 5 - The company will hold a quarterly performance briefing on November 17, 2025, to discuss the third quarter results [23][25] - Investors can submit questions in advance through the Shanghai Stock Exchange's website or via email [24][27] - The meeting will be conducted in an interactive online format [29]

Core Viewpoint - The company plans to use its reserves to offset accumulated losses by the end of 2024, aiming to enhance investor returns and support high-quality development [1][2]. Group 1: Financial Situation - As of December 31, 2024, the company's accumulated losses amount to RMB 1.45 billion, with surplus reserves of RMB 118 million and capital reserves of RMB 6.5767 billion [1]. - The accumulated losses are primarily due to past operational results, and the proposed capital reserve offset will come entirely from shareholder contributions in the form of share premiums [1]. Group 2: Proposed Plan - The company suggests using RMB 118 million from surplus reserves and RMB 1.332 billion from capital reserves to fully offset the accumulated losses, totaling RMB 1.45 billion [1]. - After the completion of the loss offset plan, surplus reserves will be reduced to RMB 0, capital reserves will decrease to RMB 5.245 billion, and accumulated losses will be fully eliminated [2].

Core Viewpoint - The company plans to use its reserves to offset accumulated losses by December 31, 2024, in order to enhance investor returns and support high-quality development [1][2] Financial Summary - As of December 31, 2024, the company's accumulated losses amount to RMB 1.45 billion, with surplus reserves of RMB 118 million and capital reserves of RMB 6.5767 billion [1] - The proposal includes using RMB 118 million from surplus reserves and RMB 1.332 billion from capital reserves to cover the total accumulated losses of RMB 1.45 billion [1] - After the loss offset plan is completed, surplus reserves will be reduced to RMB 0, capital reserves will decrease to RMB 5.245 billion, and accumulated losses will be fully offset to RMB 0 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 使用公積金彌補虧損的基本情況 根 據 由 德 勤 華 永 會 計 師 事 務 所（特 殊 普 通 合 夥）出 具 的 本 公 司2024年度財務報表 及 審 計 報 告，於2024年12月31日，母 公 司 累 計 虧 損 為 人 民 幣1,450,342,128.90元， 其盈餘公積為人民幣118,388,703.29元，而其資本公積為人民幣6,576,729,725.03元。 內幕消息 使用公積金彌補虧損 本 公 告 由 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09(2)及13.10B條以及香港法例第571章證券及期貨條例 第XIVA部 內 幕 消 息 條 文（定 義 見 上 市 規 則 ...